Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | PKM | P14618 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | STAT1 | P42224 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8603235 | 0.90 | SLC2A1 (0.76) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2478174 | 0.85 | NPC1 (0.68) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1662754 | 0.85 | MEN1 (0.84) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL412846 | 0.84 | MEN1 (0.74) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20982659 | 0.82 | NPC1 (0.85) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6243395 | 0.82 | NPC1 (1.00) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL12837269 | 0.80 | ALOX5 (0.70) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL415718 | 0.80 | NPC1 (0.75) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL18715523 | 0.80 | NPC1 (0.75) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28500114 | 0.80 | NPC1 (0.56) | NPC1SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763925-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2017-09-19 | — | — | US | disclosed |
| EP-3095783-A1 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2016-11-23 | — | — | EP | disclosed |
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-9314456-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2016-04-19 | — | — | US | disclosed |
| EP-2907813-A1 | Antibacterial Compound | Summit Corporation Plc (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-8975416-B2 | Antibacterial compounds | SUMMIT CORPORATION PLC (GB) | 2015-03-10 | — | — | US | disclosed |
| EP-2373631-B1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORP PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC | 2012-01-26 | — | — | US | disclosed |
| EP-2373631-A2 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063996-A2 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | NPC1 512/4885SMN1; SMN2 2597/4885MEN1 3400/4885 |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | RPN2, MRPL21, ALPI | NPC1 509/4885SMN1; SMN2 2666/4885MEN1 3476/4885 |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | NPC1 512/4885SMN1; SMN2 2597/4885MEN1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.